Derbyshire CPAG Bulletin



Clinical Policy Advisory Group (CPAG)

CLINICAL & GOVERNACE POLICIES UPDATED PROCEDURES OF LIMITED CLINICAL VALUE POLICIES

Research evidence shows that some interventions are not clinically effective or only effective when they are performed in specific circumstances. The purpose of the Procedures of Limited Clinical Value (PLCV) policy is to clarify the commissioning intentions of the Integrated Care Board (ICB). The ICB will only fund treatment for clinically effective interventions that are then delivered to the appropriate cohort of patients. When updating Clinical Policies CPAG undertakes Stakeholder engagement with Specialists/Consultants/Clinicians.

Clinical Policy	Key Changes	
Blepharoplasty Policy (Full routine review)	NHS Derby and Derbyshire ICB has deemed that blepharoplasty should not routinely be commissioned unles the criteria within the policy are met.	
	The following minor amendments have been made to the policy:	
	Policy criteria has been re-worded for further clarity	
	Link to the NHSDDICB Meibomian Cyst (Chalazion) Policy added	
	There has been no new significant robust evidence or new national guidance that has been published since the policy was last reviewed in October 2020 that requires a change reflecting in the policy's criteria commissioning stance.	
	Summary of policy and management Blepharoplasty is a surgical procedure that involves the removal of excess skin, fat or muscle from the eyelids	
	The aim of the procedure is to improve hooded or drooping eyelids. The procedure usually involves an incision along the natural creases of the upper lids or just below the lashe	
	in the lower lids, which are extended into the crow's feet at the corner of the eyes. Excess fat, skin and saggin muscle is then removed and the incision is stitched up. The procedure can be carried out under local or general anesthetic.	
Hypnotherapy Position Statement Full routine review)	NHS Derby and Derbyshire ICB will not routinely commission the use of hypnotherapy as a stand-alon treatment.	
,	There has not been publication of substantial robust evidence since the position statement was published of October 2020 to support the use of hypnotherapy as a stand-alone treatment.	
Gamete Storage Policy Feedback Partial review	NHS Derby and Derbyshire ICB has agreed that Gamete Storage should be commissioned only when eligibility criteria listed within the policy are met.	
following stakeholder query)	The following minor amendments have been made to the policy following feedback received from Public Healt and to clarify equity for those undertaking surgery:	
	 Paragraph relating to women undergoing Gynecological surgery has been re-worded Inclusion of Glossary to help explain the terminology used within the policy. 	
	Stakeholder feedback was also received in response to the CPAG decision made in March 2023, not tremove the criteria "patient has no living children" to be eligible for Gamete storage. CPAG agreed no change to the policy and to await the outcome of an East Midlands review which is current taking place to look at the ethical consideration relating to exclusion of those that have a living child for a fertility policies.	
	Summary of policy and management	
	This policy relates to the preservation of gametes (oocytes and semen) and embryos, in post-pubertal patients in advance of chemotherapy or radiotherapy treatment for cancer or conditions requiring male urological of female gynecological surgery that carries a high risk of infertility. Adverse effects associated with a number of medical treatments can impact on fertility, either by direct injury or via systemically administered agents. It some cases, the individual's fertility will return after the treatment is completed but in other cases fertility never returns or is severely impaired. Technological advances mean that cryopreservation of semen, oocytes embryos and ovarian/testicular tissue offers opportunities to preserve fertility prior to the start of treatment. Cryopreservation is a technique that freezes an individual's eggs or sperm for use in future fertility treatment.	
InVitro Fertilisation (IVF) Intracytoplasmic	NHS Derby and Derbyshire ICB, in line with its principles for procedures of limited clinical value has deeme that IVF and ICSI should not routinely be commissioned unless the criteria within the policy are met.	
Sperm Injection (ICSI) within Tertiary Infertility Services Policy	Following a response to an MP letter regarding access to IVF, for couples who have already self-funde treatment, the following minor amendment has been made to the policy to clarify eligibility criteria wording for number of cycles provided by DDICB:	
(Partial review following enquiry)	 The recommendation section of the policy has been updated with a separate box for "Number of Cycles" added to "Eligibility criteria" table. All other references to "number of cycles" within this section have been removed. 	
	Summary of policy and management In vitro fertilisation (IVF) is one of the main methods used to help people conceive. Treatment begins wi	

stimulation of the ovaries and includes collecting eggs and sperm, fertilising the eggs outside the woman's

body, and placing 1 or 2 of the embryos into the womb. This policy reflects the NICE guidelines that access to high level treatments including IVF should be offered to women up to the age of 42. In women aged 36 or over, assessment should be considered after 6 months of unprotected regular intercourse since, the chance of successful conception is lower and the window of opportunity for intervention is less. For women aged up to 42 years who have not conceived after 2 years of regular unprotected intercourse or a course of artificial insemination (in line with local ICB policy), this should be taken as an indication for consideration of IVF.

MISCELLANEOUS INFORMATION		
Statement	Summary	
Publication of	The Evidence Based Interventions List 3 (EBI3) guidance has been published (May 2023).	
Evidence Based Interventions List 3 (EBI3) Guidance	The EBI programme began in 2018 to ensure a national approach to quality improvement and align best practice across the healthcare system. EBI3 builds on EB1 and 2 which remain valid valid. This is a national initiative led by the Academy of Medical Royal Colleges to improve the quality of care. It's aims are to ensure healthcare providers focus only on interventions which are known to be effective, based on the best available medical evidence. The EBI programme also actively seeks to reduce geographic health inequalities.	
	The EBI 3 Document sets out 10 interventions. A stakeholder engagement exercise will be undertaken with the main providers for all 10 interventions to confirm assurances that the system is aligned to the EBI recommendations. This process was agreed at CPAG in September 2022. All 10 interventions are to be included in an Overarching Statement for EBI3.	
	Clinical coding for List 3 is being explored. It is a national view that tracking the implementation of the guidance will not be possible in the short term while this coding is being developed.	
Evidence Based Interventions (EBI)/Procedures of	As part of the wider ICB recovery plan, it has been identified that there are potential system efficiency savings for activity carried out by providers for Evidence Based Interventions (EBI).	
Limited Clinical Value (PLCV) Benchmarking Report	A report has been produced by the ICB Business Informatics (BI) Department using the Model Hospital system data to benchmark the EBI category 1 and the higher risk areas for EBI category 2 activity for Derbyshire ICB to both regional and national recommended peers. The data from the Model Hospital is taken from a national dashboard.	
	CPAG agreed that the Prior Approval process and the Cosmetic referral Assessment Service (CAS) remain a valuable assurance tool for Procedures of Limited Clinical Value (PLCV)/EBI.	
CPAG Stakeholder Engagement Process	CPAG has reviewed the process for stakeholder feedback and agreed the proposed changes in the operating model for stakeholder engagement, which includes a two-stage verification process and strengthening the role of CPAG provider members. As a result, CPAG were assured (as stated in all communications) that if no response is received after the agreed timeframe, the coversheet will reflect the positive engagement, considered to be agreement with the current policy.	
Assisted Fertility Policy Review for East Midlands ICBs	A collaborate approach to the commissioning of fertility services has been agreed across the five East Midlands ICBs and will be undertaken by Solutions for Public Health (SPH) with Nottingham ICB acting as Lead commissioner. Taking a collaborate approach minimises inequity of access based on geography and also supports providers with service delivery across a wide geographical area.	
	The scope of the project has been outlined and the final report is due to be submitted on the 28 th September 2023 (subject to key dependencies).	
Glossop Transition for Clinical Policies, Non- Clinical Significant	As part of the internal Glossop transition plan, the Medicines Management department have been asked to undertake a programme of work to align five identified areas.	
Variation Policies and Procedures of Limited	CPAG agreed the preferred options for IVF and non-significant variation policies and Procedures of Limited Clinical Value/Cosmetic referral Assessment Service.	
Clinical Value (PLCV)/Cosmetic referral Assessment	A paper will be tabled at the next Population Health and Strategic Commissioning Committee (PHSCC) meeting, to ratify the preferred options.	
Service (CAS)	PPI forms are to be completed for all future policy reviews to assess whether the legal duty is triggered, to inform, involve or consult/engage with individuals.	
	The CPD team are to engage with Glossop stakeholders via the General Practice Provider Board.	
Update to Procedures of Limited Clinical Value (PLCV) Prior Approval Policy	Following a stakeholder query, the Procedures of Limited Clinical Value (PLCV) templates for the Electronic Referral Service (e-RS) have been amended to make it clearer that they are to be used for referrals using the e-RS service and not for an opinion from secondary care.	
template for e-RS Individual Funding Requests (IFR)	CPAG reviewed the IFR Screening cases for May 2023 and are assured that no areas for service development have been identified.	
Screening Cases		

NICE INTERVENTIONS, DIAGNOSTICS, MEDICAL AND HEALTH TECHNOLOGIES AND INNOVATION PROGRAMMES

The DDICB does not commission and will not fund any procedure or technology assessed by NICE under their IPG, MTG, DTG, MIB or HTE programmes unless:

- the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved AND
- the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'
- OR the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'
- OR the NICE DTG makes a recommendation as an option for use

- OR the NICE MIB has evaluated the innovation
- OR the NICE HTE has made a recommendation for use while evidence is being generated

The following NICE programme outputs were noted by the group for the month of May 2023:

PROMITED		nme outputs were noted by the group for the month of May	
dependent chronic researchor failure from high spinal cord injuries Automated ankite brachial pressure index measurement devices to offeet peripheral stretal disease in people commission DG53 MRI franco below systems for disgnosing prostate cands Chronic Care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment 1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (11)s in primary or community openerated. A strategio PA-100 analyse with the PA AST panel U-0501 (Sysmax Astrego) U-screen (Savyro) Diagnostics). They show promise in guiding antimicrobial prescribing, and further research streen (Savyro) Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of organic studies would allow the risks and benefits of early routine use in the NNRS to be undership or using the street of the commended for antiformostics (hourand) Filestouth Human (SSI Diagnostics). 1.2 Further research is recommended on how: a courate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test is function; see section 4). The research is recommended on how: a courate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test is function; see section 4). There is established the representation of the repairs can be used as treathment options for adults with depression while antibiotic prescribing (see section 4). HTE8 Digitally enabled therapies for adults with depression while antibiotic prescribing (see section 4). There digitally enabled therapies can be used as treathment options for adults with depression while antibiotic prescribing (see section 4). The research is recommended to a depression of the proposed of early seed of the pression of the proposed of the pression	IPG/MTG/DTG/HTE/MIB	Description	Outcome
departed critical respiratory failure from their spiral cord injuries Automated ankle trachal pressure index measurement devices to detect peripheral arterial disease in peculia commission DG53 MRI fraction below systems for diagnosing prostate commission RI fraction below systems for diagnosing prostate commission Port of Carat rests for urinary tract infections to increase an increase and programment of the programment o	IPG762	Intramuscular diaphragm stimulation for ventilator-	NICE recommends special arrangements, DDICB
DG52 Automated ankle brachial pressure index measurement devices to detect peripheral strend disease in people with lag utions. Mix busines for disease in people with lag utions. Mix busines for disease in people and the provider and the prov	0.02		
Automated ankite trackist pressure index measurement devices to detect perspend anterial disease in people with leg ulcers MRI basic bloops yesterns for diagnosing prostate cancer. MRI basic bloops yesterns for diagnosing prostate cancer. Point-of-care tests for uninary tract infections to improve artimicrobial prescribing, early value assessment. 1.1 The following point-ocate tests are not recommended for early routine use for suspended uninary tract infections (UTIs) in primary or community care settings in the NHS while further evidence is generated. • Astrago PA: 100 analyses with the PA AST panel U. 6501 (Syamex Astrago). • Uriscreen (Savyon Diegnostics). They show promise in guiding antimicrobial prescribing. They show promise in guiding antimicrobial prescribing. They show promise in guiding antimicrobial prescribing would allow the risks and benefits of early routine use in NHS primary or community care settings for suspected UTIS: • Diastide, Dispiterals and Chromo Streek (Novamed). 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIS: • Diastide, Dispiterals and Chromo Streek (Novamed). Flexical Human (SS Dispiteds). • Uricula, Uricula throat in these settings. 1.2 Further research is recommended on how. • accurate the tests are in detecting and identifying bacteria and testing for arbibiots used by enough to improve artimicrobial prescribing in these settings. 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with with the provider submitting a robust, evidenced based business are to several and testing for processing loss sessions may be used once they have Digital Technology Assessment Critical (TAC), approval and an NHS Talking Therapies for article and depression digitally enabled therapies assessment from NHS England. Therapies			do not commission
devices to detect peripheral actorial disease in people with load utiliers with load utiliers MRI fusion biologys systems for disagnosing prostate cannot. MRI fusion biologys systems for disagnosing prostate cannot. Point-of-care tests for unnay tract infections to morove attentionable acceptance, and value assessment. 1.1 The following point-of-care tests are not recommended for early routine use for suspected unnary tract infections (UTIs) in primary or community care settings in the NHS while further evidence is generated: A atrago PA-100 analyser with the PA AST panel U-0501 (Syamox Astrego) 1.3 The following authure-based point-of-care tests are not recommended for early routine use in InNES primary or community care settings for suspected UTIs: D-05016 (Disprostos) 1.2 Further research of ChromoStreak (Novamed) Flexicult Human (SSI Disgnostica) 1.2 Further research is recommended on how: ecounter the tests are in detecting and intention of the provider suspensibility (depending on the tests for indetecting and intention provider in the standard arrangements (1.1, 1-1) the tests affect antibiotic prescribing in these settings. 1.2 Further research is recommended on how: ecounter the tests are in detecting and intentity in bacteria and testing for aribiditic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing in these sections 4.1 • the tests affect antibiotic prescribing in these sections of the provider submitting a robust, evidenced based business can be used on the services. These tenspies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for availate and the provider submitting a robust, evidenced based business can be used once they have Digital Technoply, Assessment Crimitic (17-4), approval and an It-S talking Therapies for availate and the provider and the sect			
devices to detect periphenal activated diseases in people with load utilities with load utilities MRI fusion biologys systems for diagnosing prostate cancel. HTE7 Point-of-care tests for unnary treat infections to morove attentionable prescribing, early value assessment 1.1 The following point-of-care tests are not ecommended for early volutine use for supected urinary tract infections (LITs) in primary or community care settings in the NHS while further evidence is generated: • Astrage PA-100 analyses with the PA AST panel U-0501 (Sysmex Astrego) • Unicared (Sayuno Biognostics). They show promise in guiding artimitrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in NHS primary or community care settings for suspected UTs: • Disalide, (byStreak and ChromoStreak (Nowmed) • Flexicult Human (SSI Diagnostics) • Unicult, Uncult trio and Unicult plus (Vidian), They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Eurther research is recommended on how- accurate the tests are of adecting and infortifying bacteria and testing for artibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect artibiotic prescribing is dese section 4.1 • the tests affect artibiotic prescribing is for suspection of the set strained practitioner or therapise in NHS Talking Therapies for adults with depression services. These technologies can be used ones the services. These technologies can be used ones the services of technologies can be used ones the services of testing the control of the services of testing the control of the services of testing the services of reliable improvement rates of reliable deterioration respective of reliable improvement rates of reliable deterioration responded by	DG52	Automated ankle brachial pressure index measurement	NICE recommends further research, DDICB do not
MRL upon biopsy systems for diagnosing prostate cancer Point-of-care tests for urinary tract infections to morrow antimicrobial prescribing santy value assessment 1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTIs) in primary or community care settings in the NHE while further orderoce is a Horizon (UTIs) in primary or community care settings in the NHE while further orderoce is a Horizon (UTIs) in primary or community care settings in the NHE while further orderoce is a Horizon (Saymo Diagnosites). They show promise in quiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in NHS primary or the NHS to be understood. 1.3 The following cultive based point-of-care tests are not recommended for early routine use in NHS primary or Diagnosics). They are not expected to plongostical in the NHE point of the NHS primary or Diagnosics in the NHS primary or Diagnosic properties of the NHS primary of the NHS primary or Diagnosic properties of the Diagnosic properties of the Diagnosic properties of the Diagnosic pr			
MRIT tasion bilatory systems for diagnosing prostate cancer Cancer Caste Cancer Caste Cancer Caste Cancer Caste Cancer Caste Caste Cancer Caste			COMMINGUION
### Point-of-care tests for uninary tract infections to improve antimicrobial prescribing, early value assessment 1.1 The following point-of-care tests are not recommended for early value assessment 1.1 The following point-of-care tests are not recommended for early value assessment 2. Assing the 100 analyser with the PA AST panel early (Symer, Astrego) 3. Part 100 analyser with the PA AST panel 4. Urisoreen (Saryon Diegnostics) They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended or early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended by the properties of the prop			
HTET Point-of-care tests for uninary tract infections to improve antimicrobial prescribing, early value assessment 1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTIS) in primary or community care settings in the NHS while further evidence is generated: Astrogo PA-100 analyser with the PA AST panel U-5507 (Sysmex Astrego) Uriscreen (Savyon Diagnostics), They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in NHS primary or community care settings for suspected UTIs. 1.3 The following culture based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs. Diasidic, DipStreak and ChromoStreak (Novamed) - Eloicult Human (SSD Diagnostics) - Uricult, Uricult trio and Uricult plus (Aldian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for artibiotic susceptibility (depending on the lest's functions; see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect ambiotic prescribing (see section 4.1) - It is test affect am	DG53	MRI fusion biopsy systems for diagnosing prostate	NICE recommends further research, DDICB do not
HTET Point-of-care tests for urinary tract infections to improve animinstobial prescribing, early value assessment in the following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTBs) in primary or community care settings in the NHS while further evidence is generated: Astrogo PA-100 analyser with the PA AST panel U-567 (Sysmex Astrego) Uriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of orgoing studies would allow the risks and benefits of early routine use in NHS primary or community care settings for suspected UTIs. 1.3 The following culture based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs. Diaside, DipStreak and ChromoStreak (Novamed)		cancer	commission
antimicrobial prescribing carly value assessment 1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTIS) in primary or community care settings in the NHS while further evidence is generated: Astreep PA-100 analyser with the PA AST panel U-060f (Sysmex Astreep) U-060f (Sysmex Astreep) They strone promise in guiding anticrobial prescribing, the part of			
antimicrobial prescribing early value assessment 1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTIs) in primary or community care settings in the NHS while further evidence is generated: Astreep PA-100 analyser with the PA AST panel U-060f (Sysmex Astreep) U-060f (Sysmex Astreep) They show promise in guiding simicrobial prescribing the part of th	HTE7	Point-of-care tests for urinary tract infections to improve	NICE does not recommend (1.1, 1.3), DDICB do
1.1 The following point-of-care tests are not recommended for early routine use for suspected urinary tract infections (UTIS) in primary or community care settings in the NHS while further evidence is generated. • Astrago PA-100 analyser with the PA AST panel U-0501 (Gysmax Astrago) • Uriscreen (Savyon Diagnostics) and further research and completion do opping studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasilde, DisStreak and ChromoStreak (Novamed) • Flexicult Human (SSD Diagnostics) • Uricult, Uricult trio and Uricult plus (Aidan). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing or artibiotic susceptibility (depending on the test a functions; see section 4.2). • the tests affect antibiotic prescribing (see section 4.2). • the tests affect antibiotic prescribing (see section 4.2). • They are digitally enabled therapies can be used as treatment options for adults with depression: 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and coost affectiveness. The therapies should be used with the service of the provided option of the			
recommended for early routine use for suspected uninary tract infections (UTIs) in primary or community care settings in the NHS while further evidence is generated: • Astrago PA-100 analyser with the PA AST panel U-0501 (Syamax Astrago) • Uriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following sulture-based point-of-care tests are not recommended for early routine use in NHS primary or controlly one service of the primary or controlly or controlly of the primary or controlly or co		artimorobial presonbing, early value assessment	Tiot commission
recommended for early routine use for suspected uninary tract infections (UTIs) in primary or community care settings in the NHS while further evidence is generated: • Astrago PA-100 analyser with the PA AST panel U-0501 (Syamax Astrago) • Uriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following sulture-based point-of-care tests are not recommended for early routine use in NHS primary or controlly one service of the primary or controlly or controlly of the primary or controlly or co			
urinary tract infections (UTIS) in primary or community care settings in the NIS while further evidence is generated: • Astrogo PA-100 analyser with the PA AST panel U-0501 (Sysmex Astrogo) • Uriscreen (Sayron Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasolide, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostics) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the lest's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2) • the tests affect antibiotic prescribing (see section 4.2) • the tests affect antibiotic prescribing (see section 4.2) • Three digitally enabled therapies for adults with depression; serf value assessment 1.1 Three digitally enabled therapies for abults with depression; serf value assessment 1.1 Three digitally enabled therapies for abults with depression while support from a trained practitioner or therapist in NHS Talking Therapies for antible for the propersion services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (S65 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable derecovery • rates of			NICE recommends further research (1.2), DDICB
urinary tract infections (UTIS) in primary or community care settings in the NIS while further evidence is generated: • Astrogo PA-100 analyser with the PA AST panel U-0501 (Sysmex Astrogo) • Uriscreen (Sayron Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasolide, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostics) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the lest's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2) • the tests affect antibiotic prescribing (see section 4.2) • the tests affect antibiotic prescribing (see section 4.2) • Three digitally enabled therapies for adults with depression; serf value assessment 1.1 Three digitally enabled therapies for abults with depression; serf value assessment 1.1 Three digitally enabled therapies for abults with depression while support from a trained practitioner or therapist in NHS Talking Therapies for antible for the propersion services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (S65 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable derecovery • rates of		recommended for early routine use for suspected	do not commission
care satings in the NHS while further evidence is generated: • Astrago PA-100 analyser with the PA AST panel U-0501 (Sysmex Astrego) • Uriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suppeted UTIS. • Disatile, DipCirea and ChromoStreak (Novamed) • Fixexicut Human (SSI Diagnostics) • Uricut, Uricut time and Uricutip lass (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how. • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the lest's furthcrise; see section 4.2°). HTE8 Dictally enabled therapies for adults with depression: early value assessment. 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost affectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Chiera (DTAC) approval and deals. Existing Therapies for anxiety and depression in the second of the control of the part of the properties of the part of th			
generated: • Astrego PA-100 analyser with the PA AST panel U-0501 (Sysmex Astrego) • Uriscreen (Savyor Diagnostics), They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasilde, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI) Diagnostic) • Uricult, Uricult frio and Uricult plus (Aidan), They are not expected to give results guickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.1) • the tests affect prescribing in these settings. 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression: sarty value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression with the commissioner and subsequent approval and many proval and cost assessment of the provider of the			
Astrego PA-100 analyser with the PA AST panel U-0501 (Sysmax Astrego) Utriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diaside, DipStreek and Chromostreek (Novamed) Flexicult Human (SSI Diagnostica) Utricult, Uricult in and Uricult plus (Aidan) They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.2). 1.1 Three digitally enabled therapies for adults with depression: sartiv value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used as treatment options for adults with depression may be supported and the support of the propersion of the propersion of the propersion (single) the used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression and the propersion of the propersio			
U-0501 (Sysmex Astrego) Uriscreen (Savyor Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following outlure-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diasilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult trio and Unicult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test situations, see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression; early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapiest in NHS Tailing and technology Assessment Criteria (DTAC), approval and an NHS. Tailing Therapies for antibiots or the second or they compared to the commission of the second or the second or the commission of the second or the second or the commission of the second or the se		generated:	
U-0501 (Sysmex Astrego) Uriscreen (Savyor Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following outlure-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diasilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult trio and Unicult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test situations, see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression; early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapiest in NHS Tailing and technology Assessment Criteria (DTAC), approval and an NHS. Tailing Therapies for antibiots or the second or they compared to the commission of the second or the second or the commission of the second or the second or the commission of the second or the se		 Astrego PA-100 analyser with the PA AST panel 	
Uriscreen (Savyon Diagnostics). They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Disalide, DipStreak and Chromostreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how. • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.2). • the tests affect antibiotic prescribing (see section 4.2). • Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression is for the provider and the state of the provider submitting are tous, violence as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally mabbled therapies assessment from NHS England. The technologies are: • Beating the Blues (686 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCoud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable deterioration rates and reasons for stopping treatment •			
They show promise in guiding antimicrobial prescribing, and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diastide, DipStreak and ChromoStreak (Novamed) • Flexucult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2) Digitally, enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with supproval 1.1 Three digitally enabled therapies should be used with supproval made an NHS Talking Therapies to anxiety and depression digitally enabled therapies to anxiety and the anxiety and depression and experience the section of the p			
and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasilde, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test structions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Dipitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies are: • Beating the Bluss (365 Health Solutions) • Depressis (Ehrypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable autility of life • resource use during and after treatment, including the average number of treatment sessions and level			
and further research and completion of ongoing studies would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasilde, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test structions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Dipitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies are: • Beating the Bluss (365 Health Solutions) • Depressis (Ehrypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable autility of life • resource use during and after treatment, including the average number of treatment sessions and level		They show promise in guiding antimicrobial prescribing.	
would allow the risks and benefits of early routine use in the NHS to be understood. 1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diaside, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an JMS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable inprovement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates of reliable member of treatment sessions and level			
1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTIs: • Diasilde, DipSreak and Chromo-Gtraak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve aritmicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test structions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Diptitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies are: • Beating the Bluse (365 Heath Solutions) • Depressis (Ehrypharm Digital Therapies of anxiety and depression digitally enabled therapies are: • Beating the Bluse (365 Heath Solutions) • Depressis (Ehrypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable recovery • rates of reliable recovery • rates of reliable many the depression and level • resource use during and after treatment, including the average number of treatment sessions and level			
1.3 The following culture-based point-of-care tests are not recommended for early routine use in NHS primary or community care settings for suspected UTS: • Diasilde, DipStreak and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult thio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in HNS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Cheria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Heath Solutions) • Depressi (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping up of care • patient experience • health-related quality of life • resource used during and after treatment, including the average number of treatment sessions and level			
not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diasilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult thio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression distilied venabled therapies sasessment from NHS England. The technologies care: Beating the Blues (366 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration determined the experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		in the NHS to be understood.	
not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diasilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult thio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression distilied venabled therapies sasessment from NHS England. The technologies care: Beating the Blues (366 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration determined the experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
not recommended for early routine use in NHS primary or community care settings for suspected UTIs: Diasilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult thio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression distilied venabled therapies sasessment from NHS England. The technologies care: Beating the Blues (366 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration determined the experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		1.3 The following culture based point of care tests are	
or community care settings for suspected UTIs: • Diasilide, DipStraek and ChromoStreak (Novamed) • Flexicult Human (SSI Diagnostica) • Uricult, Uricult rito and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1). • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: • arity value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression dicitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable quality of life • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
Diabilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.1) three digitally enabled therapies on a section 4.1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression diaptily enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
Diabilde, DipStreak and ChromoStreak (Novamed) Flexicult Human (SSI Diagnostica) Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.1) three digitally enabled therapies on a section 4.1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression diaptily enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		or community care settings for suspected UTIs:	
Firexicult Human (SSI Diagnostica) Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how. • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2) Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprevix (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates and reasons for stopping treatment rates of reliable depresion: health-related quality of life resource use during and after treatment, including the average number of treatment, essions and level		· · · · · · · · · · · · · · · · · · ·	
Uricult, Uricult trio and Uricult plus (Aidian). They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1). the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS Enaland. The technologies are: Beating the Bulsue (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable improvement rates of reliable recovery rates of reliable improvement rates of reliable improvement rates of reliable improvement rates of reliable recovery rates of reliable improvement rates of reliable recovery			
They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.2). • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable recovery rates of reliable recovery rates of reliable deterioration rates and reasons for stopping treatment rates of reliable agreement e health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		Flexicult Human (SSI Diagnostica)	
They are not expected to give results quickly enough to improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.2). • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable recovery rates of reliable recovery rates of reliable deterioration rates and reasons for stopping treatment rates of reliable agreement e health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		Uricult Uricult trio and Uricult plus (Aidian)	
improve antimicrobial prescribing in these settings. 1.2 Further research is recommended on how: • accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). • Digitally enabled therapies for adults with depression: early value assessment: 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapisit in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Circlina (DTAC) approval and an NHS Talking Therapies for anxiety and depression of digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable deterioration • rates of reliable recovery • rates of reliable mprovement • rates of reliable recovery • rates of reliable and easons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
1.2 Further research is recommended on how: accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable improvement rates of reliable improvement rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of releabe improvement health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2) Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates of reliable improvement rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable of the rate of the rate of reliable of the rate o		improve antimicrobial prescribing in these settings.	
accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2) Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates of reliable improvement rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable of the rate of the rate of reliable of the rate o			
accurate the tests are in detecting and identifying bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) the tests affect antibiotic prescribing (see section 4.2) Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates of reliable improvement rates of reliable deterioration rates of reliable improvement rates of reliable improvement rates of reliable of the rate of the rate of reliable of the rate o		1.2 Further research is recommended on how:	
bacteria and testing for antibiotic susceptibility (depending on the test's functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: arriv value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technologies can be used once they have Digital Technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable recovery • rates of reliable deterioration • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates of reliable deterioration • rates of reliable deterioration • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
(depending on the tests functions; see section 4.1) • the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
the tests affect antibiotic prescribing (see section 4.2). Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable deterioration rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates and reasons for stopping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
HTE8 Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates and reasons for stopping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		(depending on the test's functions; see section 4.1)	
HTE8 Digitally enabled therapies for adults with depression: early value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of reliable deterioration rates and reasons for stopping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		the tests affect antihintic prescribing (see section)	
Digitally enabled therapies for adults with depression: aarly value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable deterioration • rates and reasons for stopping treatment • rates of reliable and text price the adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
aarly value assessment 1.1 Three digitally enabled therapies can be used as treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable deterioration rates and reasons for stopping treatment rates of relabed deterioration rates and reasons for stopping treatment rates of relabed adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level	LITEO		NIOE
submitting a robust, evidenced based business case to the commissioner and subsequent approval further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relabse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level	HIE8		
atreatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable improvement rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level		early value assessment	1.2) – not commissioned without the provider
atreatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable improvement rates of reliable deterioration rates of reliable deterioration and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			submitting a robust, evidenced based business
treatment options for adults with depression while further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of reliable recovery • rates of reliable deterioration • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level		1.1 Three digitally enabled therapies can be used as	
further evidence is generated on their clinical and cost effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable deterioration rates and reasons for stopping treatment rates of reliabse deterioration rates and reasons for stopping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
effectiveness. The therapies should be used with support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an JNHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			approvai
support from a trained practitioner or therapist in NHS Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies sassessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level		effectiveness. The therapies should be used with	NICE recommends further research (1.3), DDICB
Talking Therapies for anxiety and depression services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level		support from a trained practitioner or therapist in NHS	do not commission
services. These technologies can be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
depression digitally enabled therapies assessment from NHS England. The technologies are: • Beating the Blues (365 Health Solutions) • Deprexis (Ethypharm Digital Therapy) • Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
NHS England. The technologies are: Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level			
 Beating the Blues (365 Health Solutions) Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 			
 Deprexis (Ethypharm Digital Therapy) Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		· · · · · · · · · · · · · · · · · · ·	
 Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		The state of the s	
 Space from Depression (SilverCloud). 1.2 Further evidence should be generated on: rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		Deprexis (Ethypharm Digital Therapy)	
1.2 Further evidence should be generated on: • rates of recovery • rates of reliable recovery • rates of reliable improvement • rates of reliable deterioration • rates and reasons for stopping treatment • rates of relapse • adverse effects and stepping up of care • patient experience • health-related quality of life • resource use during and after treatment, including the average number of treatment sessions and level			
 rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		• Space nom Depression (SilverCloud).	
 rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		40-11	
 rates of recovery rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		1.2 Further evidence should be generated on:	
 rates of reliable recovery rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 			
 rates of reliable improvement rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		-	
 rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		-	
 rates of reliable deterioration rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		rates of reliable improvement	
 rates and reasons for stopping treatment rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		-	
 rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 			
 rates of relapse adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		 rates and reasons for stopping treatment 	
 adverse effects and stepping up of care patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 			
 patient experience health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		•	
 health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		adverse effects and stepping up of care	
 health-related quality of life resource use during and after treatment, including the average number of treatment sessions and level 		patient experience	
 resource use during and after treatment, including the average number of treatment sessions and level 		·	
the average number of treatment sessions and level			
the average number of treatment sessions and level		resource use during and after treatment, including	
Or guidance provided (defined by nearthoate			
		or guidance provided (defined by fleatificate	<u>l</u>

professional grade and time) baseline data, including the demographics and symptom severity of the people using the technology, and their risk classification. 1.3 The following technologies should only be used as part of a research study that has been approved by an ethics committee, once they have appropriate regulatory approval: Iona Mind (Iona Mind) Minddistrict (Minddistrict) Wysa (Wysa). Find out more in the research only recommendations section of the guidance. HTE9 Digitally enabled therapies for adults with anxiety NICE recommends standard arrangements (1.1, disorders: early value assessment 1.2) - not commissioned without the provider submitting a robust, evidenced based business 1.1 Six digitally enabled therapies can be used as case to the commissioner and subsequent treatment options for adults with anxiety disorders while approval further evidence is generated on their clinical and cost effectiveness, once they have appropriate approval. NICE recommends further research (1.3), DDICB do not commission The following technologies can only be used once they have Digital Technology Assessment Criteria (DTAC) approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment from NHS England: Beating the Blues (365 Health Solutions) for generalised anxiety symptoms or unspecified anxiety disorder iCT PTSD (OxCADAT) for post-traumatic stress disorder (PTSD) iCT SAD (OxCADAT) for social anxiety disorder Space from Anxiety (SilverCloud) for generalised anxiety symptoms or unspecified anxiety disorder. The following technologies can only be used once they have CE or UK Conformity Assessed (UKCA) mark approval, DTAC approval and an NHS Talking Therapies for anxiety and depression digitally enabled therapies assessment: Perspectives (Koa Health) for body dysmorphic disorder (BDD) Spring (Cardiff University) for PTSD. Low intensity interventions should be supported by a psychological wellbeing practitioner and high intensity interventions by a high intensity therapist in NHS Talking Therapies for anxiety and depression services.

1.2 Further evidence should be generated on:

rates and reasons for stopping treatment

adverse effects and stepping up of care

resource use during and after treatment, including the average number of treatment sessions and level of guidance provided (defined by healthcare

baseline data including the demographics and symptom severity of the people using the technology and their risk classification.

1.3 The following technologies should only be used as part of a research study that has been approved by an ethics committee, once they have appropriate

Cerina (NoSuffering), Iona Mind (Iona Mind), Minddistrict (Minddistrict), Resony (RCube Health)

rates of recovery
rates of reliable recovery
rates of reliable improvement
rates of reliable deterioration

rates of relapse

regulatory approval:

patient experience

health-related quality of life

professional grade and time)

and Wysa (Wysa) for generalised anxiety disorder (GAD) or generalised anxiety symptoms	
Cerina, Minddistrict and Space from OCD (SilverCloud) for obsessive compulsive disorder (OCD)	
 Minddistrict and SilverCloud programmes for health anxiety, panic disorder with or without agoraphobia, social anxiety disorder and phobias. 	
Find out more in the <u>research only recommendations</u> <u>section</u> of this guidance.	

Our ICB continues to monitor and implement IPGs with our main providers.